Microbix Biosystems Inc. (MBX.TO)
CAD 0.35
(0.0%)
CAD 0.35
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.02 Million CAD | 34.39% |
| 2022 | 8.2 Million CAD | -20.11% |
| 2021 | 10.27 Million CAD | 14.42% |
| 2020 | 8.97 Million CAD | -1.25% |
| 2019 | 9.09 Million CAD | 1.51% |
| 2018 | 8.95 Million CAD | -20.48% |
| 2017 | 11.26 Million CAD | 13.13% |
| 2016 | 9.95 Million CAD | 0.87% |
| 2015 | 9.87 Million CAD | 21.0% |
| 2014 | 8.15 Million CAD | 16.62% |
| 2013 | 6.99 Million CAD | -25.47% |
| 2012 | 9.38 Million CAD | 8.33% |
| 2011 | 8.66 Million CAD | -0.01% |
| 2010 | 8.66 Million CAD | 12.87% |
| 2009 | 7.67 Million CAD | 9.93% |
| 2008 | 6.98 Million CAD | 98.42% |
| 2007 | 3.51 Million CAD | 41.96% |
| 2006 | 2.47 Million CAD | 109.77% |
| 2005 | 1.18 Million CAD | 8.3% |
| 2004 | 1.09 Million CAD | 10.18% |
| 2003 | 990.3 Thousand CAD | 64.25% |
| 2002 | 602.92 Thousand CAD | -33.67% |
| 2001 | 908.94 Thousand CAD | -20.48% |
| 2000 | 1.14 Million CAD | 14.3% |
| 1999 | 1 Million CAD | -50.0% |
| 1998 | 2 Million CAD | 81.82% |
| 1997 | 1.1 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 10.16 Million CAD | 7.22% |
| 2024 Q3 | 9.71 Million CAD | -4.48% |
| 2024 Q1 | 9.48 Million CAD | -14.03% |
| 2023 FY | 11.02 Million CAD | 34.39% |
| 2023 Q1 | 9.23 Million CAD | 12.5% |
| 2023 Q2 | 9.82 Million CAD | 6.46% |
| 2023 Q4 | 11.02 Million CAD | -5.35% |
| 2023 Q3 | 11.65 Million CAD | 18.54% |
| 2022 Q1 | 9.02 Million CAD | -12.12% |
| 2022 Q4 | 8.2 Million CAD | -4.03% |
| 2022 FY | 8.2 Million CAD | -20.11% |
| 2022 Q2 | 9.13 Million CAD | 1.16% |
| 2022 Q3 | 8.55 Million CAD | -6.37% |
| 2021 Q2 | 9.74 Million CAD | 5.4% |
| 2021 Q3 | 9.14 Million CAD | -6.07% |
| 2021 Q1 | 9.24 Million CAD | 2.94% |
| 2021 FY | 10.27 Million CAD | 14.42% |
| 2021 Q4 | 10.27 Million CAD | 12.28% |
| 2020 Q4 | 8.97 Million CAD | 0.53% |
| 2020 FY | 8.97 Million CAD | -1.25% |
| 2020 Q3 | 8.93 Million CAD | 2.14% |
| 2020 Q2 | 8.74 Million CAD | -10.56% |
| 2020 Q1 | 9.77 Million CAD | 7.52% |
| 2019 FY | 9.09 Million CAD | 1.51% |
| 2019 Q1 | 9.66 Million CAD | 7.85% |
| 2019 Q2 | 9.61 Million CAD | -0.5% |
| 2019 Q4 | 9.09 Million CAD | -7.05% |
| 2019 Q3 | 9.78 Million CAD | 1.76% |
| 2018 Q2 | 8.55 Million CAD | -4.91% |
| 2018 Q4 | 8.95 Million CAD | -7.65% |
| 2018 FY | 8.95 Million CAD | -20.48% |
| 2018 Q1 | 8.99 Million CAD | -20.11% |
| 2018 Q3 | 9.69 Million CAD | 13.36% |
| 2017 FY | 11.26 Million CAD | 13.13% |
| 2017 Q4 | 11.26 Million CAD | 8.9% |
| 2017 Q3 | 10.34 Million CAD | 0.85% |
| 2017 Q2 | 10.25 Million CAD | 6.79% |
| 2017 Q1 | 9.6 Million CAD | -3.54% |
| 2016 Q4 | 9.95 Million CAD | -7.48% |
| 2016 FY | 9.95 Million CAD | 0.87% |
| 2016 Q1 | 9.57 Million CAD | -2.96% |
| 2016 Q2 | 9.93 Million CAD | 3.75% |
| 2016 Q3 | 10.76 Million CAD | 8.29% |
| 2015 Q1 | 8.22 Million CAD | 0.88% |
| 2015 Q3 | 9.11 Million CAD | -0.02% |
| 2015 Q2 | 9.11 Million CAD | 10.83% |
| 2015 FY | 9.87 Million CAD | 21.0% |
| 2015 Q4 | 9.87 Million CAD | 8.25% |
| 2014 Q3 | 8.19 Million CAD | 3.68% |
| 2014 Q4 | 8.15 Million CAD | -0.49% |
| 2014 Q2 | 7.9 Million CAD | 19.72% |
| 2014 FY | 8.15 Million CAD | 16.62% |
| 2014 Q1 | 6.6 Million CAD | -5.58% |
| 2013 Q4 | 6.99 Million CAD | -21.18% |
| 2013 Q1 | 8.92 Million CAD | -4.95% |
| 2013 FY | 6.99 Million CAD | -25.47% |
| 2013 Q2 | 9.01 Million CAD | 1.05% |
| 2013 Q3 | 8.87 Million CAD | -1.54% |
| 2012 Q4 | 9.38 Million CAD | 12.19% |
| 2012 FY | 9.38 Million CAD | 8.33% |
| 2012 Q3 | 8.36 Million CAD | -1.49% |
| 2012 Q2 | 8.49 Million CAD | -1.84% |
| 2012 Q1 | 8.65 Million CAD | -0.14% |
| 2011 Q1 | 7.8 Million CAD | -9.93% |
| 2011 FY | 8.66 Million CAD | -0.01% |
| 2011 Q4 | 8.66 Million CAD | -0.75% |
| 2011 Q3 | 8.72 Million CAD | 0.68% |
| 2011 Q2 | 8.66 Million CAD | 11.09% |
| 2010 FY | 8.66 Million CAD | 12.87% |
| 2010 Q4 | 8.66 Million CAD | 8.51% |
| 2010 Q2 | 7.67 Million CAD | -1.16% |
| 2010 Q3 | 7.98 Million CAD | 4.08% |
| 2010 Q1 | 7.76 Million CAD | 1.12% |
| 2009 Q3 | 7.83 Million CAD | 0.52% |
| 2009 Q4 | 7.67 Million CAD | -2.07% |
| 2009 Q1 | 7.05 Million CAD | 1.04% |
| 2009 FY | 7.67 Million CAD | 9.93% |
| 2009 Q2 | 7.79 Million CAD | 10.53% |
| 2008 Q4 | 6.98 Million CAD | 32.9% |
| 2008 Q2 | 3.89 Million CAD | 6.56% |
| 2008 Q1 | 3.65 Million CAD | 3.79% |
| 2008 FY | 6.98 Million CAD | 98.42% |
| 2008 Q3 | 5.25 Million CAD | 34.99% |
| 2007 Q4 | 3.51 Million CAD | 16.95% |
| 2007 Q1 | 2.54 Million CAD | 2.57% |
| 2007 FY | 3.51 Million CAD | 41.96% |
| 2007 Q2 | 2.93 Million CAD | 15.49% |
| 2007 Q3 | 3 Million CAD | 2.47% |
| 2006 FY | 2.47 Million CAD | 109.77% |
| 2006 Q4 | 2.47 Million CAD | 23.6% |
| 2006 Q3 | 2 Million CAD | 6.73% |
| 2006 Q2 | 1.87 Million CAD | 34.86% |
| 2006 Q1 | 1.39 Million CAD | 17.91% |
| 2005 Q4 | 1.18 Million CAD | 10.69% |
| 2005 Q3 | 1.06 Million CAD | 0.01% |
| 2005 Q2 | 1.06 Million CAD | 4.77% |
| 2005 Q1 | 1.01 Million CAD | -6.62% |
| 2005 FY | 1.18 Million CAD | 8.3% |
| 2004 Q4 | 1.09 Million CAD | -16.97% |
| 2004 FY | 1.09 Million CAD | 10.18% |
| 2004 Q1 | 880.66 Thousand CAD | -11.07% |
| 2004 Q2 | 982.81 Thousand CAD | 11.6% |
| 2004 Q3 | 1.31 Million CAD | 33.72% |
| 2003 Q2 | 992.19 Thousand CAD | -11.01% |
| 2003 Q4 | 990.3 Thousand CAD | -12.77% |
| 2003 Q3 | 1.13 Million CAD | 14.42% |
| 2003 FY | 990.3 Thousand CAD | 64.25% |
| 2003 Q1 | 1.11 Million CAD | 84.93% |
| 2002 Q1 | 887.26 Thousand CAD | -2.39% |
| 2002 FY | 602.92 Thousand CAD | -33.67% |
| 2002 Q2 | 781.3 Thousand CAD | -11.94% |
| 2002 Q3 | 732.37 Thousand CAD | -6.26% |
| 2002 Q4 | 602.92 Thousand CAD | -17.68% |
| 2001 FY | 908.94 Thousand CAD | -20.48% |
| 2001 Q4 | 908.94 Thousand CAD | -9.42% |
| 2001 Q3 | 1 Million CAD | -5.47% |
| 2001 Q2 | 1.06 Million CAD | -6.71% |
| 2001 Q1 | 1.13 Million CAD | -0.45% |
| 2000 Q3 | 1 Million CAD | -16.67% |
| 2000 Q2 | 1.2 Million CAD | 33.33% |
| 2000 Q1 | 900 Thousand CAD | -10.0% |
| 2000 FY | 1.14 Million CAD | 14.3% |
| 2000 Q4 | 1.14 Million CAD | 14.3% |
| 1999 Q1 | 1.3 Million CAD | -35.0% |
| 1999 Q3 | 1.2 Million CAD | 0.0% |
| 1999 Q2 | 1.2 Million CAD | -7.69% |
| 1999 Q4 | 1 Million CAD | -16.67% |
| 1999 FY | 1 Million CAD | -50.0% |
| 1998 Q2 | 1.4 Million CAD | 16.67% |
| 1998 Q1 | 1.2 Million CAD | 9.09% |
| 1998 FY | 2 Million CAD | 81.82% |
| 1998 Q4 | 2 Million CAD | 81.82% |
| 1998 Q3 | 1.1 Million CAD | -21.43% |
| 1997 Q2 | 900 Thousand CAD | 0.0% |
| 1997 Q3 | 1.1 Million CAD | 22.22% |
| 1997 Q4 | 1.1 Million CAD | 0.0% |
| 1997 Q1 | 900 Thousand CAD | 0.0% |
| 1997 FY | 1.1 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | 11.169% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 56.829% |
| Helix BioPharma Corp. | 1.57 Million CAD | -598.451% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | 20.903% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -204.319% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | 2.03% |
| Sernova Corp. | 9.59 Million CAD | -14.973% |